Hualan Biological Engineering Inc operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hualan Biological Engineering Inc with three other
companies in this sector in China:
Tonghua Dongbao Medicines Company Limited
sales of 2.03 billion Chinese Renmimbi [US$300.63 million]
of which 96%
China Biologic Products, Inc.
(2.27 billion Chinese Renmimbi [US$336.18 million]
of which 100%
was Human Blood Product), and
Beijing Tiantan Biologic.
(2.10 billion Chinese Renmimbi [US$310.33 million]
of which 99%
was Biological products industry).
Hualan Biological Engineering Inc reported sales of 1.93 billion Chinese Renmimbi (US$286.45 million)
December of 2016.
increase of 31.6%
versus 2015, when the company's sales were 1.47 billion Chinese Renmimbi.
Sales at Hualan Biological Engineering Inc have increased during each of the previous five years
(and since 2011, sales have increased a total of 101%).
Sales of Other Operations saw an increase
that was more than double the company's growth rate: sales were up
66.8% in 2016, from
6.58 million Chinese Renmimbi to 10.97 million Chinese Renmimbi.
Not all segments of Hualan Biological Engineering Inc experienced an increase in sales in 2016:
sales of Vaccine Products fell 2.0% to 108.96 million Chinese Renmimbi.